4DMT Appoints Kristian Humer as Chief Financial Officer
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company’s financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience spanning corporate finance, strategic operations and healthcare investment banking. During his tenure at Citi, he held progressively senior roles, culminating as Managing Director in Citi’s Healthcare Investment Banking Group, where he worked from 2010 to 2021. He advised clients across the global
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.MarketBeat
- 4DMT Announces New Employment Inducement GrantsGlobeNewswire
- 4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- 4DMT Provides Company Update and Anticipated Development Milestones for 2026GlobeNewswire
FDMT
Earnings
- 11/10/25 - Beat
FDMT
Sec Filings
- 1/26/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 3
- FDMT's page on the SEC website